NEW YORK (GenomeWeb News) – Siemens Healthcare this week said that it has established a new research lab focused on molecular diagnostics in Cologne, Germany.
The medical imaging and diagnostics giant said that the initial focus of the research labs will be on breast cancer diagnostics. It said that it would employ biochips in developing the tests, but did not say whether the chips were developed internally or are based on another company’s technology.
Siemens noted that it currently has 40 employees in Cologne developing molecular diagnostic tests for cancer.
“Viewed from the perspective of Siemens, a medicine that is more strongly based on molecular medical and knowledge-based techniques will be able to make important long-term contributions toward improving the quality and increasing the efficiency of healthcare,” Donal Quinn, CEO of the Diagnostics Division of Siemens Healthcare, said in a statement.